Novel Glutamatergic Agents for Major Depressive Disorder and Bipolar Disorder

Overview

Journal Pharmacol Biochem Behav

Publisher Elsevier

Specialties Biochemistry
Pharmacology
Psychology
Social Sciences

Date 2011 Oct 6

PMID 21971560

Citations 41

Authors

Rodrigo Machado-Vieira

Lobna Ibrahim

Ioline D Henter

Carlos A Zarate Jr

Affiliations

Soon will be listed here.

Abstract

Mood disorders such as major depressive disorder (MDD) and bipolar disorder (BPD) are common, chronic, recurrent mental illnesses that affect the lives and functioning of millions of individuals worldwide. Growing evidence suggests that the glutamatergic system is central to the neurobiology and treatment of these disorders. Here, we review data supporting the involvement of the glutamatergic system in the pathophysiology of mood disorders as well as the efficacy of glutamatergic agents as novel therapeutics.

Citing Articles

GABA and its receptors' mechanisms in the treatment of insomnia.

Zhu W, Huang L, Cheng H, Li N, Zhang B, Dai W Heliyon. 2024; 10(23):e40665.

PMID: 39654705 PMC: 11626785. DOI: 10.1016/j.heliyon.2024.e40665.

Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression.

Vecera C, Courtes A, Jones G, Soares J, Machado-Vieira R Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004437 PMC: 10675154. DOI: 10.3390/ph16111572.

Variation along P2RX7 interacts with early traumas on severity of anxiety suggesting a role for neuroinflammation.

Kristof Z, Gal Z, Torok D, Eszlari N, Sutori S, Erdelyi-Hamza B Sci Rep. 2023; 13(1):7757.

PMID: 37173368 PMC: 10182087. DOI: 10.1038/s41598-023-34781-w.

Effects of the Radix Ginseng and Semen Ziziphi Spinosae drug pair on the GLU/GABA-GLN metabolic cycle and the intestinal microflora of insomniac rats based on the brain-gut axis.

Qiao T, Wang Y, Liang K, Zheng B, Ma J, Li F Front Pharmacol. 2023; 13:1094507.

PMID: 36618926 PMC: 9811267. DOI: 10.3389/fphar.2022.1094507.

Blood Glutamate Scavenging With Pyruvate as a Novel Preventative and Therapeutic Approach for Depressive-Like Behavior Following Traumatic Brain Injury in a Rat Model.

Frank D, Gruenbaum B, Shelef I, Zvenigorodsky V, Severynovska O, Gal R Front Neurosci. 2022; 16:832478.

PMID: 35237125 PMC: 8883046. DOI: 10.3389/fnins.2022.832478.

References

Rothstein J, Patel S, Regan M, Haenggeli C, Huang Y, Bergles D . Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005; 433(7021):73-7. DOI: 10.1038/nature03180. View

Katoh-Semba R, Asano T, Ueda H, Morishita R, Takeuchi I, Inaguma Y . Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. FASEB J. 2002; 16(10):1328-30. DOI: 10.1096/fj.02-0143fje. View

Svenningsson P, Tzavara E, Witkin J, Fienberg A, Nomikos G, Greengard P . Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci U S A. 2002; 99(5):3182-7. PMC: 122493. DOI: 10.1073/pnas.052712799. View

Borza I, Bozo E, Barta-Szalai G, Kiss C, Tarkanyi G, Demeter A . Selective NR1/2B N-methyl-D-aspartate receptor antagonists among indole-2-carboxamides and benzimidazole-2-carboxamides. J Med Chem. 2007; 50(5):901-14. DOI: 10.1021/jm060420k. View

Machado-Vieira R, Salvadore G, Luckenbaugh D, Manji H, Zarate Jr C . Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry. 2008; 69(6):946-58. PMC: 2699451. DOI: 10.4088/jcp.v69n0610. View

Palucha A, Branski P, Klak K, Sowa M . Chronic imipramine treatment reduces inhibitory properties of group II mGlu receptors without affecting their density or affinity. Pharmacol Rep. 2007; 59(5):525-30. View

McCormick L, Ponto L, Pierson R, Johnson H, Magnotta V, Brumm M . Metabolic correlates of antidepressant and antipsychotic response in patients with psychotic depression undergoing electroconvulsive therapy. J ECT. 2007; 23(4):265-73. DOI: 10.1097/yct.0b013e318150d56d. View

Brennan B, Hudson J, Jensen J, McCarthy J, Roberts J, Prescot A . Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology. 2009; 35(3):834-46. PMC: 3055603. DOI: 10.1038/npp.2009.191. View

Judd L, Akiskal H, Schettler P, Endicott J, Maser J, Solomon D . The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002; 59(6):530-7. DOI: 10.1001/archpsyc.59.6.530. View

10.

Teng C, Demetrio F . Memantine may acutely improve cognition and have a mood stabilizing effect in treatment-resistant bipolar disorder. Braz J Psychiatry. 2006; 28(3):252-4. DOI: 10.1590/s1516-44462006000300020. View

11.

Svenningsson P, Bateup H, Qi H, Takamiya K, Huganir R, Spedding M . Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine. Eur J Neurosci. 2007; 26(12):3509-17. DOI: 10.1111/j.1460-9568.2007.05952.x. View

12.

Zarate Jr C, Du J, Quiroz J, Gray N, Denicoff K, Singh J . Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci. 2003; 1003:273-91. DOI: 10.1196/annals.1300.017. View

13.

Deakin J, Lees J, McKie S, Hallak J, Williams S, Dursun S . Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry. 2008; 65(2):154-64. DOI: 10.1001/archgenpsychiatry.2007.37. View

14.

Chaki S, Yoshikawa R, Hirota S, Shimazaki T, Maeda M, Kawashima N . MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology. 2004; 46(4):457-67. DOI: 10.1016/j.neuropharm.2003.10.009. View

15.

Paul I, Skolnick P . Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci. 2003; 1003:250-72. DOI: 10.1196/annals.1300.016. View

16.

Cosford N, Tehrani L, Roppe J, Schweiger E, Smith N, Anderson J . 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem. 2003; 46(2):204-6. DOI: 10.1021/jm025570j. View

17.

Sanacora G, Zarate C, Krystal J, Manji H . Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008; 7(5):426-37. PMC: 2715836. DOI: 10.1038/nrd2462. View

18.

Schoepp D, Wright R, Levine L, Gaydos B, Potter W . LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress. 2003; 6(3):189-97. DOI: 10.1080/1025389031000146773. View

19.

Thase M, Haight B, Richard N, Rockett C, Mitton M, Modell J . Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry. 2005; 66(8):974-81. DOI: 10.4088/jcp.v66n0803. View

20.

Liebrenz M, Borgeat A, Leisinger R, Stohler R . Intravenous ketamine therapy in a patient with a treatment-resistant major depression. Swiss Med Wkly. 2007; 137(15-16):234-6. DOI: 10.4414/smw.2007.11852. View